- Home
- CYBR vs BBIO Comparison
CYBR vs BBIO Comparison
Compare CYBR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBR
- BBIO
- Stock Information
- Founded
- CYBR 1999
- BBIO 2015
- Country
- CYBR Israel
- BBIO United States
- Employees
- CYBR N/A
- BBIO N/A
- Industry
- CYBR Computer Software: Prepackaged Software
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CYBR Technology
- BBIO Health Care
- Exchange
- CYBR Nasdaq
- BBIO Nasdaq
- Market Cap
- CYBR 15.5B
- BBIO 6.7B
- IPO Year
- CYBR 2014
- BBIO 2019
- Fundamental
- Price
- CYBR $355.44
- BBIO $34.48
- Analyst Decision
- CYBR Strong Buy
- BBIO Strong Buy
- Analyst Count
- CYBR 33
- BBIO 12
- Target Price
- CYBR $406.21
- BBIO $57.09
- AVG Volume (30 Days)
- CYBR 562.1K
- BBIO 3.2M
- Earning Date
- CYBR 05-13-2025
- BBIO 04-29-2025
- Dividend Yield
- CYBR N/A
- BBIO N/A
- EPS Growth
- CYBR N/A
- BBIO N/A
- EPS
- CYBR N/A
- BBIO N/A
- Revenue
- CYBR $1,000,742,000.00
- BBIO $127,415,000.00
- Revenue This Year
- CYBR $34.10
- BBIO $13.67
- Revenue Next Year
- CYBR $19.75
- BBIO $118.02
- P/E Ratio
- CYBR N/A
- BBIO N/A
- Revenue Growth
- CYBR 33.10
- BBIO N/A
- 52 Week Low
- CYBR $223.41
- BBIO $21.62
- 52 Week High
- CYBR $421.00
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- CYBR 60.17
- BBIO 49.67
- Support Level
- CYBR $358.24
- BBIO $33.92
- Resistance Level
- CYBR $367.10
- BBIO $39.16
- Average True Range (ATR)
- CYBR 9.93
- BBIO 1.43
- MACD
- CYBR 2.79
- BBIO -0.16
- Stochastic Oscillator
- CYBR 91.06
- BBIO 31.05
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.